Log In
Print
BCIQ
Print
Print this Print this
 

SynCon malaria DNA vaccine

  Manage Alerts
Collapse Summary General Information
Company Inovio Pharmaceuticals Inc.
DescriptionSynCon DNA vaccine targeting the pre-erythrocytic stage of the malaria parasite Plasmodium falciparum delivered with electroporation
Molecular Target P. falciparum circumsporozoite (CS) protein B9 (B9) (CSP) ; Acid phosphatase 5 tartrate resistant (ACP5) (TRAP)
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPreclinical
Standard IndicationMalaria
Indication DetailsPrevent malaria infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today